CATALENT, INC.

Shareholders of CATALENT, INC.

New Jersey publishes no shareholder register, and ownership of a business entity registered in New Jersey cannot be established from the state’s business records. The position set out below rests on the company’s own filings with the U.S. Securities and Exchange Commission.

CATALENT, INC. is wholly owned by Creek Parent, Inc., a Delaware corporation that is itself a wholly owned subsidiary of Novo Holdings A/S. On 18 December 2024, Creek Merger Sub, Inc. merged into Catalent, Inc. under the Agreement and Plan of Merger dated 5 February 2024, with Catalent surviving the merger as a wholly owned subsidiary of Creek Parent, Inc. Each share of common stock outstanding immediately before the effective time was converted into the right to receive USD 63.50 in cash, and holders of common stock ceased to have any rights as stockholders other than the right to that consideration. Catalent’s Form 15-12G, filed 30 December 2024, certifies the approximate number of holders of record as one.

The merger was approved by stockholders at a special meeting held on 29 May 2024: 142,764,710 shares voted for, 1,120,850 against and 17,174 abstained, out of 180,974,218 shares of common stock outstanding on the record date.

Institutional holdings that existed before the transaction no longer describe the ownership of this company. The twenty holder rows carried alongside this profile, which include Vanguard Group Inc, Capital World Investors, BlackRock Inc., Janus Henderson Group PLC, T. Rowe Price Investment Management, Nomura Holdings Inc., State Street, Veritas Asset Management, Corvex Management LP and Leonard Green & Partners, L.P., are institutional positions in the formerly listed company. Every share they held was cancelled for cash at the effective time on 18 December 2024. None of those managers or funds holds shares in Catalent, Inc. today, and no percentage from that list is reproduced here.

Those percentages would not describe ownership even for the period they relate to. Each is calculated as a share of whichever holders the data provider sampled rather than as a share of issued capital, so the figures are inflated and are not meaningfully additive. The list also double-counts positions by naming both an asset manager and individual funds it advises as separate holders, for example Vanguard Group Inc alongside Vanguard 500 Index Fund and Vanguard Total Stock Market Index Fund.

No natural person is identified as an ultimate beneficial owner in any source consulted. The ultimate controlling party is the Novo Nordisk Foundation (Novo Nordisk Fonden), a Danish commercial foundation, which has no natural-person owner. The intervening chain is set out in the group structure section.

Data availability

New Jersey does not publish shareholders or beneficial owners for registered business entities, and the New Jersey business search at njportal.com did not accept connections when tested on 30 September 2026, so the register was not read. Because Catalent terminated the registration of its common stock on 30 December 2024, no beneficial ownership filings (Schedule 13D or 13G, or Forms 3, 4 and 5) have been made for this issuer since that date. Beyond the Form 15 certification of a single holder of record, no public filing states the current share register, and the share registers of Creek Parent, Inc. and of the intermediate holding entities were not consulted.

Sources

• U.S. Securities and Exchange Commission, Catalent, Inc., Form 8-K filed 18 December 2024 (completion of merger, change in control): sec.gov (retrieved 30 September 2026)
• U.S. Securities and Exchange Commission, Catalent, Inc., Form 15-12G filed 30 December 2024: sec.gov (retrieved 30 September 2026)
• U.S. Securities and Exchange Commission, Catalent, Inc., Form 8-K filed 29 May 2024 (special meeting voting results): sec.gov (retrieved 30 September 2026)
• Novo Holdings A/S, “Novo Holdings completes acquisition of Catalent”, 18 December 2024: novoholdings.com (retrieved 30 September 2026)

Directors and officers of CATALENT, INC.

The take-private transaction replaced the board. Every member of the board of directors in office immediately before the merger ceased to be a director at the effective time on 18 December 2024. Catalent’s Form 8-K of that date names those outgoing directors as Michael J. Barber, Steven K. Barg, J. Martin Carroll, Rolf Classon, Frank A. D’Amelio, John J. Greisch, Gregory T. Lucier, Alessandro Maselli, Donald E. Morel, Jr., Stephanie Okey, Michelle R. Ryan and Jack Stahl. The same filing states that the board of the surviving corporation, effective as of and immediately following the effective time, consisted of two people: Alessandro Maselli and John J. Greisch. It also states that the officers of the company at the effective time continued as officers of the surviving corporation.

That Form 8-K is the last filing to state Catalent’s board, because the company terminated its registration on 30 December 2024 and no longer files with the SEC. The composition set out below is taken from Catalent’s own published corporate information, retrieved on 30 September 2026. It carries no date of its own and it is not a filing, so it evidences the position as published rather than as of a certified date.

Board of directors, as published by the company:

• John Greisch, Chairman
• Alessandro Maselli, President and Chief Executive Officer
• Jonathan Levy, director
• Sue Mahony, director
• Charles Patten, director
• Marie-France Tschudin, director
• Tim Walbert, director

Group Executive Committee, as published by the company:

• Alessandro Maselli, President and Chief Executive Officer
• Matti Masanovich, Senior Vice President and Chief Financial Officer
• Joseph A. Ferraro, Senior Vice President, General Counsel, Chief Compliance Officer and Secretary
• Lisa Evoli, Senior Vice President and Chief Human Resources Officer
• Aris Gennadios, Group President, Pharma and Consumer Health
• Scott Gunther, Senior Vice President, Quality and Regulatory Affairs
• Tom Hawkeswood, Senior Vice President, Global Operations
• Ricky Hopson, Group President, Clinical and Specialty Services, and Chief of Staff
• Charles Lickfold, Senior Vice President and Chief Technology Officer
• David McErlane, Group President, Biologics

Two of these offices are corroborated by filings. Alessandro Maselli and John J. Greisch are the two directors named in the Form 8-K of 18 December 2024 as constituting the board immediately after the merger. Joseph A. Ferraro signed Catalent’s Form 15-12G on 30 December 2024 as Senior Vice President, General Counsel, Chief Compliance Officer and Secretary, which confirms that office after the merger closed.

Nationality is recorded as “Not disclosed” for every individual named above. It is not published by the company and is not stated in any filing consulted, and it is not inferred here from a person’s name or from a place of business.

Data availability

The fourteen officer rows carried alongside this profile record no position, no appointment date and no resignation date, and mark all fourteen as active, so they cannot establish who holds which office, or since when, or whether a person still serves. Five of those fourteen, Paul Surdez, Michael J. Hatzfeld, Jr., Michael J. Grippo, Lorenzo Carletti and Ricardo Pravda, do not appear on the company’s currently published board or executive committee, and no filing establishes that they hold office now; they are therefore not presented as current officers. Three rows carry academic or professional credentials appended to the surname, namely “J.d.”, “Ph.d.” and “M.b.a.”; these are data artefacts rather than parts of a name and have been removed above. The company publishes the Group President, Pharma and Consumer Health as Aris Gennadios, whereas the record holds the fuller form Aristippos Gennadios. Seven individuals published by the company, the directors Jonathan Levy, Sue Mahony, Charles Patten, Marie-France Tschudin and Tim Walbert and the executives Tom Hawkeswood and David McErlane, do not appear in the record at all. No source consulted gives dates of appointment for the reconstituted board, so the period between 18 December 2024 and today is not covered by a dated source. Nothing in the underlying record was altered.

Sources

• U.S. Securities and Exchange Commission, Catalent, Inc., Form 8-K filed 18 December 2024, Item 5.02: sec.gov (retrieved 30 September 2026)
• U.S. Securities and Exchange Commission, Catalent, Inc., Form 15-12G filed 30 December 2024 (signature block): sec.gov (retrieved 30 September 2026)
• Catalent, “About Us”, published board of directors and Group Executive Committee: catalent.com (retrieved 30 September 2026)

Group structure of CATALENT, INC.

CATALENT, INC. is a wholly owned subsidiary of Creek Parent, Inc., a Delaware corporation that is wholly owned by Novo Holdings A/S of Denmark. The chain was created by the merger completed on 18 December 2024 under the Agreement and Plan of Merger dated 5 February 2024 among Catalent, Inc., Creek Parent, Inc. and Creek Merger Sub, Inc. Catalent’s Form 8-K filed 18 December 2024 reports the completion of that merger and the resulting change in control of the registrant. Novo Holdings A/S stated on the same date that it had completed the acquisition in an all-cash transaction at an enterprise value of approximately USD 16.5 billion.

Novo Holdings A/S describes itself as the holding and investment company of the Novo Nordisk Foundation (Novo Nordisk Fonden), responsible for managing the Foundation’s assets and wealth. The ultimate controlling party of Catalent, Inc. is therefore the Novo Nordisk Foundation, a Danish commercial foundation.

Novo Holdings also stated on 18 December 2024 that it would sell three of Catalent’s sites to Novo Nordisk A/S: the fill-finish sites at Anagni in Italy, Bloomington in Indiana, United States, and Brussels in Belgium. Catalent’s Form 8-K of the same date records that Novo Nordisk A/S would acquire those three sites and related assets from Novo Holdings shortly following the merger. Those sites are consequently not expected to remain within the Catalent group.

Catalent’s own subsidiaries are listed in Exhibit 21.1 to its Form 10-K for the fiscal year ended 30 June 2024. That exhibit names 75 subsidiaries as of 30 June 2024, wholly owned unless otherwise indicated, and is the authoritative statement of Catalent’s own structure. They are almost entirely Catalent-branded entities in the United States, the United Kingdom, Italy, Belgium, France, Germany, Switzerland, the Netherlands, Japan, China, Singapore, Canada, Argentina, Brazil, Uruguay, Puerto Rico and the Cayman Islands. The principal operating company is Catalent Pharma Solutions, Inc. (Delaware). The entities in that list not carrying the Catalent name are PTS Intermediate Holdings LLC (Delaware), R.P. Scherer Technologies, LLC (Nevada), Raritan Valley Insurance Company (New Jersey) and Redwood Bioscience Inc. (Delaware). Catalent France Beinheim S.A. is listed as 99.85 per cent held rather than wholly owned. The list is dated 30 June 2024 and so predates both the merger and the transfer of the three fill-finish sites.

The hierarchy carried alongside this profile is feed data rather than a filing, and it does not depict Catalent’s group. That tree is rooted at Novo Nordisk Fonden (DK 10582989) and then Novo Holdings A/S (DK 24257630), which is the correct ultimate chain and is consistent with the filings cited above. Beneath Novo Holdings, however, the visible nodes are almost entirely the Xellia group: Xellia Holdco A/S (DK 34880549), New Xellia Group A/S (DK 35235299), Otnortopco AS (NO 991814183), Xellia Group AS (NO 992106034) and Xellia Pharmaceuticals ApS (DK 61094628) with its subsidiaries in Hong Kong, China, Hungary, Italy, Croatia, India and the United States, together with Mkg Holdco K/S (DK 46140532). Xellia is a separate Novo Holdings portfolio company and is not part of Catalent. CATALENT, INC. itself does not appear among the visible top-level nodes of that tree. The hierarchy therefore depicts part of Novo Holdings’ wider portfolio rather than Catalent’s own corporate structure, and no Xellia entity should be read as a subsidiary, parent or affiliate of Catalent.

Data availability

Catalent terminated the registration of its common stock on 30 December 2024 and files no further reports, so Exhibit 21.1 as of 30 June 2024 is the most recent subsidiary list the company has published. Changes since that date, including the completed transfer of the Anagni, Bloomington and Brussels sites, are not reflected in any public filing available for this entity. Neither Creek Parent, Inc. nor the intermediate holding entities between Novo Holdings A/S and Catalent, Inc. file with the SEC; the Danish and Delaware registry records for those entities were not consulted, so the number of intervening tiers is not established here. The New Jersey register, which does not publish group structure in any event, did not accept connections when tested on 30 September 2026.

Sources

• U.S. Securities and Exchange Commission, Catalent, Inc., Exhibit 21.1 (Subsidiaries) to Form 10-K for the fiscal year ended 30 June 2024: sec.gov (retrieved 30 September 2026)
• U.S. Securities and Exchange Commission, Catalent, Inc., Form 8-K filed 18 December 2024: sec.gov (retrieved 30 September 2026)
• Novo Holdings A/S, “Novo Holdings completes acquisition of Catalent”, 18 December 2024: novoholdings.com (retrieved 30 September 2026)
• Novo Holdings A/S, “About”: novoholdings.com (retrieved 30 September 2026)